Recursion Pharmaceuticals (NasdaqGS:RXRX) recently announced a $500 million Follow-on Equity Offering and revealed mixed earnings results for Q4 2024, which showed declining quarterly sales and ...
Recursion Pharmaceuticals is a leader in TechBio with potential to bring in $200M in near-term milestones and $20B in future ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback